Document is current
Any future updates will be listed below
-
Authors
Sugimoto, Atsushi https://orcid.org/0000-0003-3311-2562
Saito, Yoshinobu https://orcid.org/0000-0002-0624-0449
Wang, Guanxiong
Sun, Qiuyan
Yin, Chuan
Lee, Ki Hong https://orcid.org/0009-0004-3640-4944
Geng, Yana
Rajbhandari, Presha https://orcid.org/0000-0003-2184-7238
Hernandez, Celine
Steffani, Marcella https://orcid.org/0000-0002-7439-7851
Qie, Jingran
Savage, Thomas https://orcid.org/0000-0002-6618-2973
Goyal, Dhruv M. https://orcid.org/0009-0007-6454-2158
Ray, Kevin C.
Neelakantan, Taruna V.
Yin, Deqi
Melms, Johannes https://orcid.org/0000-0002-5410-6586
Lehrich, Brandon M.
Yasaka, Tyler M. https://orcid.org/0000-0002-8482-0369
Liu, Silvia
Oertel, Michael
Lan, Tian
Guillot, Adrien https://orcid.org/0000-0002-6002-9986
Peiseler, Moritz
Filliol, Aveline https://orcid.org/0000-0002-1345-8147
Kanzaki, Hiroaki
Fujiwara, Naoto
Ravi, Samhita https://orcid.org/0000-0002-6731-734X
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
Brosch, Mario
Hampe, Jochen
Remotti, Helen
Argemi, Josepmaria https://orcid.org/0000-0003-1696-7753
Sun, Zhaoli
Kendall, Timothy J. https://orcid.org/0000-0002-4174-2786
Hoshida, Yujin https://orcid.org/0000-0001-9430-1426
Tacke, Frank https://orcid.org/0000-0001-6206-0226
Fallowfield, Jonathan A. https://orcid.org/0000-0002-5741-1471
Blockley-Powell, Storm K. https://orcid.org/0009-0009-8519-9904
Haeusler, Rebecca A. https://orcid.org/0000-0002-6973-9845
Steinman, Jonathan B.
Pajvani, Utpal B.
Monga, Satdarshan P. https://orcid.org/0000-0002-8437-3378
Bataller, Ramon
Masoodi, Mojgan
Arpaia, Nicholas https://orcid.org/0000-0002-0657-0528
Lee, Youngmin A.
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
Augustin, Hellmut G. https://orcid.org/0000-0002-7173-4242
Schwabe, Robert F. https://orcid.org/0000-0003-4571-2098
- License Information
-
More Information
Article History
Received: 4 March 2024
Accepted: 21 January 2025
First Online: 12 March 2025
Competing interests
: J.A.F. serves as a consultant or advisory board member for Resolution Therapeutics, Kynos Therapeutics, Ipsen, River 2 Renal, Stimuliver and Global Clinical Trial Partners, and has received research grant funding from Intercept Pharmaceuticals and Genentech. F.T. has received research support from AstraZeneca, MSD and Gilead Consulting, and honoraria for lectures from Novo Nordisk, AstraZeneca, Gilead, Abbvie, Alnylam, BMS, Intercept, Falk, Inventiva, MSD, Pfizer, Novartis, Merz, Sanofi and GSK. B.R.S. is listed as an inventor on patents and patent applications involving small-molecule drug discovery, ferroptosis and immunostaining; holds equity in Sonata Therapeutics; co-founded and serves as a consultant to Exarta Therapeutics and ProJenX; and serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld. S.P.M. has received research funding from Alnylam, Fog Pharmaceuticals and serves as a consultant or on the scientific advisory board of Alnylam, Genentech, Surrozen, Vicero, Mermaid Bio, Antlera and UbiquiTx. R.F.S. has received research funding from Takeda via the Takeda-Columbia-NYU alliance. The other authors declare no competing interests.
